Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $169.10M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +30.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +30.3% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | $1.39B | $43.01 | Not rated | -21.4 | +153.14% |
Alto Neuroscience, Inc. NYSE:ANRO | $1.18B | $29.54 | Not rated | -9.8 | +68.88% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.33% |
Aura Biosciences, Inc. NASDAQ:AURA | $739.97M | $7.11 | Not rated | -3.7 | +32.16% |
Annexon, Inc. NASDAQ:ANNX | $642.26M | $3.92 | Not rated | -4.8 | +8.44% |
Altimmune, Inc. NASDAQ:ALT | $319.98M | $1.65 | Not rated | -3.7 | -67.10% |
Larimar Therapeutics, Inc. NASDAQ:LRMR | $313.73M | $3.02 | Not rated | -1.8 | -11.80% |
DBV Technologies S.A. NASDAQ:DBVT | $263.50M | $11.02 | Not rated | -8.3 | -28.28% |
Amarin Corporation plc NASDAQ:AMRN | $235.37M | $11.38 | Not rated | -9.9 | -32.56% |
enGene Holdings Inc. NASDAQ:ENGN | $161.51M | $2.41 | Not rated | -1.8 | -75.00% |
Continue the stock analysis
Jump to another research area for this company.